Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library

Similar documents
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

Multiplex target enrichment using DNA indexing for ultra-high throughput variant detection

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

Investigating rare diseases with Agilent NGS solutions

Back to the Basics: Methyl-Seq 101

Cytogenetics 101: Clinical Research and Molecular Genetic Technologies

SCALPEL MICRO-ASSEMBLY APPROACH TO DETECT INDELS WITHIN EXOME-CAPTURE DATA. Giuseppe Narzisi, PhD Schatz Lab

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Performance Characteristics BRCA MASTR Plus Dx

DNA-seq Bioinformatics Analysis: Copy Number Variation

Identifying Mutations Responsible for Rare Disorders Using New Technologies

Small RNA Sequencing. Project Workflow. Service Description. Sequencing Service Specification BGISEQ-500 SERVICE OVERVIEW SAMPLE PREPARATION

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffinembedded lung adenocarcinoma samples

Analysis with SureCall 2.1

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis

FONS Nové sekvenační technologie vklinickédiagnostice?

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

CRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery

High Throughput TruSeq Stranded mrna Library Construction on the Biomek FX P

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

Somatic cancer applications of NGS in in vitro Diagnostics.

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Illuminating the genetics of complex human diseases

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Simple, rapid, and reliable RNA sequencing

NGS in tissue and liquid biopsy

TOWARDS ACCURATE GERMLINE AND SOMATIC INDEL DISCOVERY WITH MICRO-ASSEMBLY. Giuseppe Narzisi, PhD Bioinformatics Scientist

ncounter Data Analysis Guidelines for Copy Number Variation (CNV) Molecules That Count NanoString Technologies, Inc.

Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer

P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University.

Identification of genomic alterations in cervical cancer biopsies by exome sequencing

No mutations were identified.

Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA

Genomic structural variation

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

Accel-Amplicon Panels

Circulating Cell-Free DNA Pre-analytics: Importance of ccfdna Stabilization and Extraction for Liquid Biopsy Applications

Supplementary Figure 1

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Selective depletion of abundant RNAs to enable transcriptome analysis of lowinput and highly-degraded RNA from FFPE breast cancer samples

AD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients

Importance of Cell Stock Concentration for Accurate Target Cell Recovery

Synthetic microrna Reference Standards Genomics Research Group ABRF 2015

Please Silence Your Cell Phones. Thank You

The Importance of Coverage Uniformity Over On-Target Rate for Efficient Targeted NGS

Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY

Liquid biopsy in lung cancer: The EGFR paradigm

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY

Molecular Characterization of Tumors Using Next-Generation Sequencing

Supplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols.

VARIANT PRIORIZATION AND ANALYSIS INCORPORATING PROBLEMATIC REGIONS OF THE GENOME ANIL PATWARDHAN

ACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology

CNV detection. Introduction and detection in NGS data. G. Demidov 1,2. NGSchool2016. Centre for Genomic Regulation. CNV detection. G.

SUPPLEMENTARY INFORMATION

Agilent s Copy Number Variation (CNV) Portfolio

ncounter TM Analysis System

Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing

MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival

Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray

Golden Helix s End-to-End Solution for Clinical Labs

Enabling Personalized

Calling DNA variants SNVs, CNVs, and SVs. Steve Laurie Variant Effect Predictor Training Course Prague, 6 th November 2017

NEXT GENERATION SEQUENCING. R. Piazza (MD, PhD) Dept. of Medicine and Surgery, University of Milano-Bicocca

September 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development

SUPPLEMENTARY INFORMATION

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Lynch Syndrome and COLARIS Testing

Enterprise Interest Thermo Fisher Scientific / Employee

!"##"$%#"&!'&$'()$(%&'*& Terapia Pediatrica e Farmacologia dello Sviluppo +,-./&01,23&34,53& :&;.<&2-.=;:3&;.;2>6-6&-.&;&

Supplementary Tables. Supplementary Figures

Victor Guryev. European Research Institute for the Biology of Ageing

MEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

CNV Detection and Interpretation in Genomic Data

PERSONALIZED GENETIC REPORT CLIENT-REPORTED DATA PURPOSE OF THE X-SCREEN TEST

Introduction to LOH and Allele Specific Copy Number User Forum

Genomic Medicine: What every pathologist needs to know

Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection

Screening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space

Optimizing Copy Number Variation Analysis Using Genome-wide Short Sequence Oligonucleotide Arrays

Assessing intercomponent. heterogeneity of biphasic uterine carcinosarcoma. December 7, 2018

Home Brewed Personalized Genomics

Dr Rick Tearle Senior Applications Specialist, EMEA Complete Genomics Complete Genomics, Inc.

Andrew Parrish, Richard Caswell, Garan Jones, Christopher M. Watson, Laura A. Crinnion 3,4, Sian Ellard 1,2

ChIP-seq data analysis

Validation of copy number variation analysis for next-generation sequencing diagnostics

Platform Approach to Cancer Discovery and Diagnostics Development

Comprehensive Analyses of Circulating Cell- Free Tumor DNA

Transcription:

Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.

Why Perform Targeted Resequencing? Focus Your Research on Relevant Regions Genetic Diseases: identify mutations that correlate to disease or contribute to genetic risk. Follow up of GWAS, re-sequence of disease associated regions Exome sequencing for discovery of mutations in rare diseases Candidate genes panels involved in disease pathways Cancer: identify somatic mutations involved in tumorigenesis or metastasis, discover germ line mutations that contribute to cancer risk. Focus on exome or cancer gene panel for comprehensive coverage of known and rare mutations Deep sequencing of cancer related regions to identify rare mutations present in heterogeneous tumor tissues

Exome Capture Comparison Study - Stanford Sept 25, 2011 Study compared the performance of three capture technologies: NimbleGen SeqCap EZ Exome Library v2.0 Agilent SureSelect Exome Illumina TruSeq Exome Comparison of single nucleotide variant (SNV) detection between exome and whole genome sequencing Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975 http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.1975.html

Exome Capture Comparison Study - Stanford Efficiency and Coverage Percentage bases covered with >10X coverage with 80M reads NimbleGen 96.8% Agilent 89.6% Illumina 90.0% NimbleGen SeqCap EZ Exome demonstrate(s) the highest efficiency target enrichment, able to adequately cover the largest proportion of its targeted bases with the least amount of sequencing. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975 http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.1975.html

Exome Capture Comparison Study - Stanford Indel Detection b. Indels detected in bases targeted c. Indels detected in RefSeq coding region In shared and RefSeq regions, NimbleGen had the highest sensitivity for detecting indels because of higher average read depth. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975 http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.1975.html

Exome Capture Comparison Study - Stanford Comparison to Whole Genome Sequencing we found that exome sequencing can identify variants that are not evident in WGS (Whole Genome Sequencing) because of greater base coverage after enrichment. Clark et al., Performance comparison of exome DNA sequencing technologies (2011) Nature Biotechnology Published online 25 September 2011 doi:1038/nbt.1975 http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.1975.html

Exome Capture Comparison Study BGI Sept 28, 2011 Study compared the performance of three capture technologies: NimbleGen SeqCap EZ Exome Library v1.0 NimbleGen Sequence Capture 2.1M Array Agilent SureSelect Exome the NimbleGen platforms showed better uniformity of coverage and greater genotype sensitivity at 30-100 folds sequencing depth. Asan et al., Comprehensive comparison of three commercial human whole-exome capture platforms (2011) Genome Biology Published online 28 September 2011, 12:R95 http://genomebiology.com/2011/12/9/r95/abstract

Exome Capture Comparison Study FINN Sept 28, 2011 Study compared the performance of two capture technologies: NimbleGen SeqCap EZ Exome Library v2.0 Agilent SureSelect Exome In our data, libraries captured with NimbleGen kits aligned more accurately to the target regions. NimbleGen SeqCap v2.0 most efficiently covered the exome with a minimum coverage of 20x... Sulonen et al., Comparison of solution-based exome capture methods for next generation sequencing (2011) Genome Biology Published online 28 September 2011, 12:R94 http://genomebiology.com/2011/12/9/r94/abstract

NimbleGen SeqCap EZ Products From small custom gene panel to Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Choice Library Capture any regions from 100kb 50Mb. Available in convenient kit sizes: 12, 24, 48, 96, 384, and 960 reactions. SeqCap EZ Exome v2.0 Library Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes.

NimbleGen SeqCap EZ Exome Products New 64Mb Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Exome Library v2.0 Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes. SeqCap EZ Exome Library v3.0 New! Superior coverage due to empirical rebalancing Targeting 64 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq, CCDS, Ensembl, Vega, Gencode, and mirbase.

SeqCap EZ Workflow Capture any targets from 100kb 50Mb with 2.1 million long oligos in solution Target Regions Prepare with Next-Gen Sequencing Adaptors SeqCap EZ (Solution Capture) Amplify DNA and Enrichment QC Sequence DNA on a Next-Gen Sequencer Genomic DNA Library Preparation Hybridization Capture and Washing Amplification and QC Sequencing

SeqCap EZ Choice Probe Design More Probes, Better Capture Simple Tiling Design (Agilent) Target Region Up to 55,000 (120mer) probes/baits tiled across the region. NimbleGen Sequence Capture Design Target Region Up to 2,100,000 (50-105mer) probes selected for the region using special algorithm. Significantly more probes, 38X. Benefits: Higher density tiling Redundancy to reduce risk Ability to move probes for better uniformity

NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ Exon 1 Exon 2 Exon 3 Minimum data required

NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ $ Exon 1 Exon 2 Exon 3 Minimum data required

NimbleGen SeqCap EZ Library Reduce Sequencing Costs Capture Uniformity Good depth Average depth Poor depth $ $ $ Exon 1 Exon 2 Exon 3 Minimum data required

NimbleGen SeqCap EZ Exome Products New 64Mb Exome Unique design process with up to 2.1 million long DNA probes to ensure high target coverage and good capture uniformity. Optimized protocols for Illumina and Roche 454 Sequencing systems SeqCap EZ Exome Library v2.0 Superior coverage due to empirical rebalancing Targeting 44 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq and CCDS, and 710 mirna genes. SeqCap EZ Exome Library v3.0 New! Superior coverage due to empirical rebalancing Targeting 64 Mb human genomic regions, covering coding exons from ~ 20K unique genes from RefSeq, CCDS, Ensembl, Vega, Gencode, and mirbase.

NimbleGen SeqCap EZ Exome Library v3 Achieve the most comprehensive coverage of coding regions 100.00% 98.00% 96.00% 94.00% 92.00% 90.00% 88.00% RefSeq Vega Gencode Ensembl CCDS mirbase SeqCap EZ Exome v3 SureSelect TruSeq

Coverage of Coding Exons How does SeqCap EZ Exome Library v3.0 compare? Gigabases of input sequence

Coverage of raw sequence How does SeqCap EZ Exome v3.0 compare?

Multiplex SeqCap EZ Illumina TruSeq Library ADAPTERS library prep (pre-cap multiplexing) capture INDEXE D INDEXE D (post-cap multiplexing) sequencing (GAIIx or HiSeq2000)

Precap Multiplexing with Illumina TruSeq Libraries Balanced distribution of indexed reads Million Read 8 Samples (4 tumor/normal pairs) Each capture reaction was sequenced with 1 lane on HiSeq (2x100bp pairedend)

SeqCap EZ Exome Pre Capture Multiplexing Experimental Summary Pre Capture vs. Post Capture Multiplexing Yoruban Trio captured with both 3 plex pre capture and 3 plex post capture Pre and post capture multiplex sequenced on separate Illumina HiSeq lanes 2x100 bp Exome 7 plex Pre Capture Multiplexing 3 Exome captures with 7 samples pre captured in each capture Each replicate sequenced on one Illumina HiSeq lane 2x100 bp Protocols for use with Illumina TruSeq Libraries Preparation Kit can be found at nimblegen.com

SeqCap EZ Exome Pre Capture Multiplexing Balanced index reads distribution compared to post capture 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 NA19238, postcap NA19239, postcap NA19240, postcap NA19238, precap NA19239, precap NA19240, precap One Lane of HiSeq v3 sequenced at 100 bp reads and subsampled to 75 Million Reads

SeqCap EZ Exome Pre Capture Multiplexing Post Capture - 3 samples Pre Capture 3 samples % On Target ~72% ~71% Average Coverage ~50x ~46x Median Coverage ~40x ~38x % bases at > 10 coverage ~93% ~93% % PCR Duplicates ~1% ~2.5% % Sensitivity ~97% ~97% % Specificity ~99% ~99% One Lane of HiSeq v3 sequenced at 100 bp reads and subsampled to 75 Million Reads

SeqCap EZ Exome Pre Capture Multiplexing Balanced distribution of indexed reads raw reads 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 NA19238 NA19239 NA19240 One Lane of HiSeq v3 sequenced at 100 bp reads and raw reads/not subsampled

SeqCap EZ Exome Pre Capture Multiplexing Av. raw reads 7 plex pre capture on 3 separate HiSeq lanes 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 Pre Capture (ave 7 plex) Pre Capture (ave 7 plex) Pre Capture (ave 7 plex) One Lane of HiSeq v3 sequenced at 100bp reads and raw reads/not subsampled

SeqCap EZ Exome Pre Capture Multiplexing Pre Capture 3 samples Pre Capture - 7 samples % On Target ~71% ~72% Average Coverage ~75x ~33x Median Coverage ~60x ~26x % bases at > 10 coverage ~95% ~87% % PCR Duplicates ~4% ~2.5% % Sensitivity ~98% ~93% % Specificity ~99% ~98% One Lane of HiSeq v3 sequenced at 100 bp reads and raw reads/not subsampled

Percent coverage SeqCap EZ Exome Pre Capture Multiplexing Coverage depth Coverage depth for 3 plex pre capture multiplexing and one lane of Illumina HiSeq

Automated SeqCap EZ Workflow Using the Caliper Sciclone NGS Workstation Optimized scripts written for the SeqCap EZ workflow Capability to load tips as needed based on number of samples 24 deck locations for more walk-away time Small size to fit on bench top Fully enclosed system for contamination protection Process 288 samples per week

NimbleGen SeqCap EZ Exome v.2.0 Automation vs. Manual Chr 22 Sequence Coverage from Automated Protocol on Sciclone Sequence Coverage from Manual Protocol Target Exons HapMap sample NA12762 was captured with either automated protocol or manual protocol with NimbleGen SeqCap EZ Exome v2.0.

IMPORTANT NOTICE Intended Use Unless explicitly stated otherwise, all Roche NimbleGen products and services referenced in this presentation are intended for the following use: For Life Science Research Only. Not for Use in Diagnostic Procedures. 454, 454 SEQUENCING, GS JUNIOR, NIMBLEGEN and SEQCAP are trademarks of Roche. All other product names and trademarks are the property of their respective owners 2011 Roche NimbleGen, Inc.

We Innovate Healthcare